BRK-B vs HQH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
HQH presents a complex profile with a stable Piotroski F-Score of 5/9 and a significant valuation discount, trading well below its Graham Number ($26.72) and Intrinsic Value ($47.5). However, these value metrics are offset by severe fundamental deterioration, specifically a -48.70% YoY revenue decline and an unsustainable dividend payout ratio of 139.13%. While historical price performance is positive, the current technical trend is heavily bearish (10/100) and liquidity is tight with a current ratio of 0.77. The stock is a value trap candidate where low multiples are justified by declining growth and dividend risk.
Compare Another Pair
Related Comparisons
BRK-B vs HQH: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Abrdn Healthcare Investors (HQH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.